Association between H19 polymorphisms and osteosarcoma risk

T.-D. He, D. Xu, T. Sui, J.-K. Zhu, Z.-X. Wei, Y.-M. Wang

Department of Orthopedics, The First People’s Hospital of Changzhou, Changzhou, Jiangsu Province, China. doctorwym51346@163.com

---

• Oncology

OBJECTIVE: The long non-coding RNA (lncRNA) H19, a maternally expressed imprinted gene, has involvement in cancer susceptibility and disease progression. However, the association between H19 polymorphisms and osteosarcoma susceptibility has remained elusive. We designed this case-control study to explore the association between H19 polymorphism and osteosarcoma risk.

PATIENTS AND METHODS: In this study, we genotyped 4 tagger SNPs of the H19 gene in a case-control study including 193 osteosarcoma cases and 393 cancer-free controls.

RESULTS: For the main effect analysis, rs217727 (G>A) was associated with osteosarcoma risk (GA/GG: adjusted OR = 1.51, 95% CI: 1.06-2.17, p = 0.024; AA/GG: adjusted OR = 1.89, 95% CI: 1.23-2.91, p = 0.004; additive model: adjusted OR = 1.35, 95% CI: 1.01-1.80, p = 0.043).

CONCLUSIONS: This finding indicates that rs217727 polymorphism may play a role in genetic susceptibility to the risk of osteosarcoma, which may improve our understanding of the potential contribution of H19 SNPs to cancer pathogenesis.